BAUDETTE, Minn., June 5, 2018 /PRNewswire/ -- ANI Pharmaceuticals,
Inc. ("ANI") (NASDAQ: ANIP) today announced that the following
three new members of the Board of Directors were elected at the
Annual Meeting of Stockholders, held on May
17, 2018:
Thomas J. Haughey held the
role of General Counsel and Secretary at Par Pharmaceutical
Companies, Inc. ("Par") from 2003 through 2016. In addition to his
role as General Counsel, he has held various additional executive
roles at Par including President from 2011 to 2012 and, most
recently, Chief Administrative Officer from 2012 to 2016. Prior to
that, Mr. Haughey held positions at Schering-Plough Corporation,
where he was Chief Counsel from 1998 to 2001 and Legal Director
from 2001 to 2003. Previously, Mr. Haughey was an attorney at
Cadwalader Wickersham & Taft and a certified public accountant
at Arthur Andersen & Co. Mr. Haughey earned a B.S. in
accounting at St. John's University and
a J.D. at the New York University School of
Law.
David B. Nash, M.D., M.B.A. is the founding dean of
the Jefferson College of Population
Health, located on the campus of Thomas
Jefferson University in Philadelphia, Pennsylvania, having taken that
position in 2008. Previously, Dr. Nash was the Chairman of the
Department of Health Policy of the Jefferson Medical College from
2003 until 2008. Dr. Nash also serves on the following public or
privately held boards: Humana, Inc. and InfoMC, and previously
served on the boards of Itrax Corporation and Endo Pharmaceuticals.
Dr. Nash is internationally recognized for his work in outcomes
management, medical staff development and quality-of-care
improvement; his publications have appeared in many articles in
major journals. Dr. Nash received his B.A. in economics (Phi Beta
Kappa) from Vassar College; his M.D.
from the University of Rochester School of
Medicine and Dentistry and his M.B.A in Health
Administration (with honors) from the Wharton School at the
University of Pennsylvania.
Patrick D. Walsh currently
serves as the chief executive officer of Avista Pharma Solutions in
Durham, North Carolina, a position
he has held since 2015. Prior to Avista, Mr. Walsh was the chief
executive officer of AAIPharma Services Corporation in Wilmington, North Carolina, a private equity
backed global provider of contract manufacturing, development and
analytical testing services. Mr. Walsh's earlier career includes
serving as chief executive officer of Kadmus Pharmaceuticals, Inc.,
in Irvine, California, and serving
as president and chief operating officer of publicly-traded Gensia
Sicor Pharmaceuticals, Inc. Mr. Walsh also serves as an independent
director of the Board of Directors of Avid Bioservices, a
publicly-traded company based in Tustin,
California and serves on its nominating committee. In
addition, prior board of director roles include serving as a
director in several pharma and biotechnology companies over the
course of his career.
Messrs. Haughey, Nash, and Walsh replace outgoing Board members
Fred Holubow, Tracy Marshbanks, and Daniel Raynor and join sitting members
Robert Brown, Thomas Penn, and Arthur
Przybyl.
Robert E. Brown, Jr., Chairman,
stated, "We are pleased to welcome Thomas
Haughey, David Nash and
Patrick Walsh to the ANI Board of
Directors. Each brings significant business experience and relevant
industry expertise to the Board. We look forward to working with
them to further the interests of ANI Pharmaceuticals. In addition,
we thank the departing members for their years of service to the
Company and its shareholders."
Subsequent to the Annual Meeting of Shareholders, the Board
reconstituted the committees of the Board as follows:
Audit and Finance Committee: Thomas Haughey (Chair), David Nash, Patrick
Walsh
Nominating and Corporate Governance Committee: Robert Brown (Chair), David Nash, Thomas
Penn
Compensation Committee: Thomas
Penn (Chair), Thomas Haughey,
Patrick Walsh
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/ani-shareholders-elect-three-new-members-to-the-board-of-directors-300659429.html
SOURCE ANI Pharmaceuticals, Inc.